tailieunhanh - Báo cáo hóa học: " Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model"

Tham khảo tài liệu 'báo cáo hóa học: " motavizumab, a neutralizing anti-respiratory syncytial virus (rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by rsv in the mouse model"', luận văn - báo cáo phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả | Virology Journal BioMed Central Short report Open Access Motavizumab A Neutralizing Anti-Respiratory Syncytial Virus Rsv Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model Asuncion Mejias 1 Susana Chavez-Bueno1 Martin B Raynor1 John Connolly2 Peter A Kiener3 Hasan S Jafri1 and Octavio Ramilo 1 Address Department of Pediatrics Division of Pediatric Infectious Diseases University of Texas Southwestern Medical Center at Dallas Texas USA 2Baylor Institute for Immunology and Research at Dallas Texas USA and 3MedImmune Inc Gaithersburg MD USA Email Asuncion Mejias - Susana Chavez-Bueno - Susana-Chavez-Bueno@ Martin B Raynor - John Connolly - JohnConn@ Peter A Kiener - KienerP@ Hasan S Jafri - Octavio Ramilo - Corresponding author Published 25 October 2007 Received II August 2007 Accepted 25 October 2007 Virology Journal 2007 4 109 doi 1743-422X-4-109 This article is available from http content 4 1 109 2007 Mejías et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Motavizumab MEDI-524 is a monoclonal antibody with enhanced neutralizing activity against RSV. In mice motavizumab suppressed RSV replication which resulted in significant reduction of clinical parameters of disease severity. We evaluated the effect of motavizumab on the local and systemic immune response induced by RSV in the mouse model. Balb c mice were intranasally inoculated with PFU RSV A2 or medium. Motavizumab was given once intraperitoneally mg mouse as prophylaxis 24 h before .